The Latest Breaking News from CMS

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Previously secret government audits reveal millions of dollars in overpayments to Medicare Advantage health plans

The measures are aimed at stopping perpetrators from using child maintenance as a form of ongoing financial abuse and control

.

An Illinois Answers Project investigation found that the insurance giant fell short in providing basic care. Now, federal officials want answers from state agencies overseeing the program.

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

In 2018, responding to a wave of overdose deaths, Congress passed legislation requiring Medicare to pay for services at opioid treatment programs for the first time.

A new benefit aimed at helping treat opioid use disorder can be hard to access for those who use Medicare Advantage plans, advocates say.

The National Investigation Agency (NIA) has filed a charge sheet against five persons in a case linked to the radicalization and recruitment of innocent youth into the Communist Party of India (Maoist). Read on for details: